General Information


We are a clinical stage gene therapy company focused on developing potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. Our gene therapies employ hematopoietic stem cells that are extracted from the patient and then modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. We believe that our approach has the potential to provide curative benefit in an outpatient setting for a range of diseases. Our initial focus is on a group of rare genetic diseases referred to as lysosomal storage diseases, which today are primarily managed with enzyme replacement therapies, or ERTs.


Employees: 34
Founded: 2015
Contact Information
Address One Kendall Square, Building 300, Suite 201, Cambridge, MA 02139
Phone Number (617) 914-8420
Web Address http://www.avrobio.com
View Prospectus: AVROBIO
Financial Information
Market Cap $439.8mil
Revenues $0 mil (last 12 months)
Net Income $-27.1 mil (last 12 months)
IPO Profile
Symbol AVRO
Exchange NASDAQ
Shares (millions): 5.3
Price range $19.00 - $19.00
Est. $ Volume $99.7 mil
Manager / Joint Managers Morgan Stanley/ Cowen/ Wells Fargo Securities
CO-Managers Wedbush Securities
Expected To Trade: 6/21/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change